Betsy C Herold1, Beatrice A Chen2, Robert A Salata3, Mark A Marzinke4, Clifton W Kelly5, Charlene S Dezzutti2, Ian McGowan2, Beth Galaska2, Lisa Levy6, Jeanna M Piper7, Sharon Hillier2, Craig W Hendrix4. 1. Departments of Pediatrics and Microbiology-Immunology, Albert Einstein College of Medicine, Bronx, New York. 2. Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, School of Medicine, Pennsylvania. 3. Department of Medicine, Case Western Reserve, Cleveland, Ohio. 4. Department of Medicine (Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington. 6. Family Health International 360, Durham, North Carolina. 7. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Tenofovir (TFV) gel partially protected against human immunodeficiency virus (HIV) in one but not subsequent trials. The disappointing results were attributed largely to poor adherence. However, timing of gel application relative to sex may impact pharmacokinetics and contribute to outcomes. Thus, we conducted a single-dose pharmacokinetic study of TFV gel applied 1 or 24 hours before or 1 hour before and 1 hour after (BAT) sex and compared results with dosing without sex. METHODS: Twenty-four couples were enrolled; cervicovaginal lavage (CVL) and tissue were collected 2 hours after sex with matching timed collections at no sex visits and assayed for drug concentrations and CVL anti-HIV activity. RESULTS: Compared with dosing without sex, median TFV concentrations after sex decreased 72% and 78% (P < .001) in CVL, 75% and 71% (P < .001) in vaginal tissue, and 75% (P = .06) and 55% (P < .001) in cervical tissue with -1 hour and -24 hour dosing, respectively. Median concentration of TFV-diphosphate also decreased significantly in cervical tissue with -1 hour, dosing. BAT dosing resulted in drug levels at least as great as those in the absence of sex. Percent inhibition of HIV infection by post-coital CVL increased significantly from median (interquartile range) of 55% (54%) in the absence of gel to 99% (7%), 77% (57%), and 100% (0.4%) with -1 hour, -24 hour, or BAT dosing, respectively, and correlated significantly with drug concentration. CONCLUSIONS: Timing of TFV gel application relative to sex significantly impacts drug levels. BAT dosing or sustained delivery may be optimal for preexposure prophylaxis.
BACKGROUND:Tenofovir (TFV) gel partially protected against human immunodeficiency virus (HIV) in one but not subsequent trials. The disappointing results were attributed largely to poor adherence. However, timing of gel application relative to sex may impact pharmacokinetics and contribute to outcomes. Thus, we conducted a single-dose pharmacokinetic study of TFV gel applied 1 or 24 hours before or 1 hour before and 1 hour after (BAT) sex and compared results with dosing without sex. METHODS: Twenty-four couples were enrolled; cervicovaginal lavage (CVL) and tissue were collected 2 hours after sex with matching timed collections at no sex visits and assayed for drug concentrations and CVL anti-HIV activity. RESULTS: Compared with dosing without sex, median TFV concentrations after sex decreased 72% and 78% (P < .001) in CVL, 75% and 71% (P < .001) in vaginal tissue, and 75% (P = .06) and 55% (P < .001) in cervical tissue with -1 hour and -24 hour dosing, respectively. Median concentration of TFV-diphosphate also decreased significantly in cervical tissue with -1 hour, dosing. BAT dosing resulted in drug levels at least as great as those in the absence of sex. Percent inhibition of HIV infection by post-coital CVL increased significantly from median (interquartile range) of 55% (54%) in the absence of gel to 99% (7%), 77% (57%), and 100% (0.4%) with -1 hour, -24 hour, or BAT dosing, respectively, and correlated significantly with drug concentration. CONCLUSIONS: Timing of TFV gel application relative to sex significantly impacts drug levels. BAT dosing or sustained delivery may be optimal for preexposure prophylaxis.
Authors: Betsy C Herold; Charlene S Dezzutti; Barbra A Richardson; Jeanne Marrazzo; Pedro M M Mesquita; Colleen Carpenter; Ashley Huber; Nicolette Louissaint; Mark A Marzinke; Sharon L Hillier; Craig W Hendrix Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: James M Smith; Priya Srinivasan; Ryan S Teller; Yungtai Lo; Chuong T Dinh; Patrick F Kiser; Betsy C Herold Journal: J Acquir Immune Defic Syndr Date: 2015-01-01 Impact factor: 3.731
Authors: James M Smith; Rachna Rastogi; Ryan S Teller; Priya Srinivasan; Pedro M M Mesquita; Umadevi Nagaraja; Janet M McNicholl; R Michael Hendry; Chuong T Dinh; Amy Martin; Betsy C Herold; Patrick F Kiser Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205
Authors: Charlene S Dezzutti; Cory Shetler; Alamelu Mahalingam; Shweta R Ugaonkar; Garry Gwozdz; Karen W Buckheit; Robert W Buckheit Journal: Antiviral Res Date: 2012-08-23 Impact factor: 5.970
Authors: Pedro M M Mesquita; Priya Srinivasan; Todd J Johnson; Rachna Rastogi; Tammy Evans-Strickfaden; Michael S Kay; Karen W Buckheit; Robert W Buckheit; James M Smith; Patrick F Kiser; Betsy C Herold Journal: Retrovirology Date: 2013-10-24 Impact factor: 4.602
Authors: Andrea R Thurman; Vivian Brache; Leila Cochon; Louise A Ouattara; Neelima Chandra; Terry Jacot; Nazita Yousefieh; Meredith R Clark; Melissa Peet; Homaira Hanif; Jill L Schwartz; Susan Ju; Mark A Marzinke; David W Erikson; Urvi Parikh; Betsy C Herold; Raina N Fichorova; Elizabeth Tolley; Gustavo F Doncel Journal: PLoS One Date: 2022-10-10 Impact factor: 3.752
Authors: Beatrice A Chen; Jingyang Zhang; Holly M Gundacker; Craig W Hendrix; Craig J Hoesley; Robert A Salata; Charlene S Dezzutti; Ariane van der Straten; Wayne B Hall; Cindy E Jacobson; Sherri Johnson; Ian McGowan; Annalene M Nel; Lydia Soto-Torres; Mark A Marzinke Journal: Clin Infect Dis Date: 2019-03-19 Impact factor: 9.079
Authors: Ekaterina Taneva; Shada Sinclair; Pedro Mm Mesquita; Brian Weinrick; Scott A Cameron; Natalia Cheshenko; Kerry Reagle; Bruce Frank; Sujatha Srinivasan; David Fredricks; Marla J Keller; Betsy C Herold Journal: JCI Insight Date: 2018-07-12
Authors: Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel Journal: PLoS One Date: 2018-06-28 Impact factor: 3.240
Authors: Andrea Ries Thurman; Jill L Schwartz; Jacques Ravel; Pawel Gajer; Mark A Marzinke; Nazita Yousefieh; Sharon M Anderson; Gustavo F Doncel Journal: PLoS One Date: 2019-05-20 Impact factor: 3.240
Authors: Louise A Ouattara; Andrea R Thurman; Terry A Jacot; Mackenzie Cottrell; Craig Sykes; Kimberly Blake; Xi Fang; Susan Ju; Nikolas C Vann; Jill Schwartz; Gustavo F Doncel Journal: J Acquir Immune Defic Syndr Date: 2022-01-01 Impact factor: 3.771